Gene therapy for renal disorders

Bibliography

• LAI LW, MOECKEL GW, LIEN YHH: Kidney-targeted liposome-mediated gene transfer in mice. Gene The]: (1997) 4:426–431.
   PubMed Web of Science ®Google Scholar
• LAI LW, CHAN DM, ERICKSON RP, HSU SJ, LIEN YHH: Correction of renal tubular acidosis in carbonic anhydrase ii- deficient mice with gene therapy. Clin. Invest. (1998) 101:1320–1325.
   Google Scholar
• SWENSON KM, KE BB, WANG T et aL: Fas ligand gene transfer to renal allografts in rats - effects on allograft survival. Transplantation (1998) 65:155–160.
   PubMed Web of Science ®Google Scholar
• LIEN YHH, LAI LW: Gene therapy for renal disorders - what are the benefits for the elderly? Drugs Aging (2002) 19:553–560.
   PubMed Web of Science ®Google Scholar
• LIEN YHH, LAI LW: Renal gene transfer - nonviral approaches. MM. Biotechnol (2003) 24:283–294.
   Google Scholar
• IMAI E: Gene therapy approach in renal disease in the 21st century. Nephrol Dial. Transplant. (2001) 16:26–34.
   PubMed Web of Science ®Google Scholar
• HANSS B, BRUGGEMAN LA: Applications of gene therapy to kidney disease. Corr. Opin. Nephrol Hypertens. (2003) 12:439–445.
   PubMed Web of Science ®Google Scholar
• TOMITA N, MORISHITA R, TOMITA T, OGIHARA T: Potential therapeutic applications of decoy oligonucleotides. Curr: Opin. MM. The]: (2002) 4:166–170.
   PubMed Web of Science ®Google Scholar
• JARAD G, SIMSKE JS, SEDOR JR, SCHELLING JR: Nucleic acid-based techniques for post-transcriptional regulation of molecular targets. Carr. Opin. Nephrol Hypertens. (2003) 12:415–421.
   PubMed Web of Science ®Google Scholar
• KHACHIGIAN LM: Dnazymes: cutting a path to a new class of therapeutics. Curr: Opin. Mol. The]: (2002) 4:119–121.
   PubMed Web of Science ®Google Scholar
• MCMANUS MT, SHARP PA: Gene silencing in mammals by small interfering RNAs. Nat. Rev Genet. (2002) 3:737–747.
   PubMed Web of Science ®Google Scholar
• XIA H, MAO Q, PAULSON HL, DAVIDSON BL: siRNA-mediated gene silencing in vitro and in vivo. Nat. Biotechnol (2002) 20:1006–1010.
   PubMed Web of Science ®Google Scholar
• NOIRI E, PERESLENI T, MILLER F, GOLIGORSKY MS: In vivo targeting of inducible no synthase with oligodeoxynucleotides protects rat kidney against ischemia. Clin. Invest. (1996) 97:2377–2383.
   Google Scholar
• HALLER H, DRAGUN D, MIETHKE A et al.: Antisense oligonucleotides for ICAM-1 attenuate reperfusion injury and renal failure in the rat. Kidney Int. (1996) 50:473–480.
   PubMed Web of Science ®Google Scholar
• DAI CS, YANG JW, LIU YH: Single injection of naked plasmid encoding hepatocyte growth factor prevents cell death and ameliorates acute renal failure in mice. J. Am. Soc. Nephrol (2002) 13:411–422.
   PubMed Web of Science ®Google Scholar
• ••Good experimental paper on HGF-basedgene therapy for renal failure.
   Google Scholar
• LIU YH, TOLBERT EM, LIN L et al.: Up-regulation of hepatocyte growth factor receptor: an amplification and targeting mechanism for hepatocyte growth factor action in acute renal failure. Kidney Int. (1999) 55:442–453.
   PubMed Web of Science ®Google Scholar
• FURUICHI K, WADA T, IWATA Y et al: Gene therapy expressing amino-terminal truncated monocyte chemoattractant protein-1 prevents renal ischemia-reperfusion injury. .1. Am. Soc. Nephrol (2003) 14:1066–1071.
   PubMed Web of Science ®Google Scholar
• AKAGI Y, ISAKA Y, ARAI M et al.: Inhibition of TGF-beta 1 expression by antisense oligonucleotides suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int. (1996) 50:148–155.
   PubMed Web of Science ®Google Scholar
• MAESHIMA Y, KASHIHARA N, YASUDA T et al.: Inhibition of mesangial cell proliferation by E2f decoy oligodeoxynucleotide in vitro and in vivo. Clin. Invest. (1998) 101:2589–2597.
   Google Scholar
• ISAKA Y, BREES DK, IKEGAYA K et al: Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nat. Med. (1996) 2(4):418–423.
   PubMed Web of Science ®Google Scholar
• ISAKA Y, AKAGI Y, ANDO Yet al.: Gene therapy by transforming growth factor-beta receptor-IgG Fc chimera suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney hat (1999) 55:465–475.
   Google Scholar
• ZHOU AH, UENO H, SHIMOMURA M et al.: Blockade of TGF-beta action ameliorates renal dysfunction and histologic progression in anti-gbm nephritis. Kidney Int. (2003) 64:92–101.
   PubMed Web of Science ®Google Scholar
• GEHL J: Electroporation: theory and methods, perspectives for drug delivery, gene therapy and research. Acta Physic] Scand. (2003) 177:437–447.
   PubMedGoogle Scholar
• NAKAMURA H, ISAKA Y, TSUJIE M et al.: Electroporation-mediated PDGF receptor-IgG chimera gene transfer ameliorates experimental glomerulonephritis. Kidney In] (2001) 59:2134–2145.
   PubMed Web of Science ®Google Scholar
• ••Good experimental paper onelectroporation-mediated gene therapy for glomerulonephritis.
   Google Scholar
• TOMITA N, MORISHITA R, LAN HY et al.: In vivo administration of a nuclear transcription factor-kappa b decoy suppresses experimental crescentic glomerulonephritis. I Am. Soc. Nephrol (2000) 11:1244–1252.
   PubMed Web of Science ®Google Scholar
• KLUTH DC, AINSLIE CV, PEARCE WP et al.: Macrophages transfected with adenovirus to express IL-4 reduce inflammation in experimental glomerulonephritis. Immunol (2001) 166:4728–4736.
   Web of Science ®Google Scholar
• ••Good experimental paper onmacrophage-based gene therapy for glomerulonephritis.
   Google Scholar
• WILSON HM, STEWART KN, BROWN PA et al.: Bone-marrow-derived macrophages genetically modified to produce IL-10 reduce injury in experimental glomerulonephritis. MM. The]: (2002) 6:710–717.
   Google Scholar
• WILSON HM, KLUTH DC: Targeting genetically modified macrophages to the glomerulus. Nephron Exp. Nephrol (2003) 94:E113–E118.
   Google Scholar
• MUNGER KA, MONTERO A, FUKUNAGA M et al.: Transfection of rat kidney with human 15-lipoxygenase suppresses inflammation and preserves function in experimental glomerulonephritis. Proc. Natl. Acad. Sci. USA (1999) 96:13375–13380.
   PubMed Web of Science ®Google Scholar
• HIGUCHI N, MARUYAMA H, KURODA T et al.: Hydrodynamics-based delivery of the viral interleukin-10 gene suppresses experimental crescentic glomerulonephritis in wistar-kyoto rats. Gene Ther. (2003) 10:1297–1310.
   PubMed Web of Science ®Google Scholar
• CHOI YK, KIM YJ, PARK HS et al.: Suppression of glomerulosclerosis by adenovirus-mediated IL-10 expression in the kidney. Gene Ther. (2003) 10:559–568.
   PubMed Web of Science ®Google Scholar
• ISAKA Y, AKAGI Y, ANDO Y, IMAI E: Application of gene therapy to diabetic nephropathy. Kidney Int. (1997) 60:S100–S103.
   Google Scholar
• AHN JD, MORISHITA R, KANEDA Y et al.: Transcription factor decoy for AP-1 reduces mesangial cell proliferation and extracellular matrix production in vitro and in vivo. Gene The]: (2004) 11(11):916–923.
   PubMed Web of Science ®Google Scholar
• TERADA Y, HANADA S, NAKAO A, KUWAHARA M, SASAKI S, MARUMO F: Gene transfer of Smad7 using electroporation of adenovirus prevents renal fibrosis in post-obstructed kidney. Kidney Int. (2002) 61:94–98.
   Google Scholar
• LAN HY, MU W, TOMITA N et al.: Inhibition of renal fibrosis by gene transfer of inducible Smad7 using ultrasound-microbubble system in rat uuo model. J. Am. Soc. Nephrol (2003) 14:1535–1548.
   PubMed Web of Science ®Google Scholar
• ••Good experimental paper on microbubble/ultrasound-based gene therapy for renal fibrosis.
   Google Scholar
• NAKAMURA H, ISAKA Y, TSUJIE M et al.: Introduction of DNA enzyme for Egr-1 into tubulointerstitial fibroblasts by electroporation reduced interstitial alpha-smooth muscle actin expression and fibrosis in unilateral ureteral obstruction (uuo) rats. Gene Ther: (2002) 9:495–502.
   PubMed Web of Science ®Google Scholar
• YANG J, DAI C, LIU Y: Systemic administration of naked plasmid encoding hepatocyte growth factor ameliorates chronic renal fibrosis in mice. Gene Ther. (2001) 8:1470–1479.
   PubMed Web of Science ®Google Scholar
• GAO XJ, MAE H, AYABE Net al.: Hepatocyte growth factor gene therapy retards the progression of chronic obstructive nephropathy. Kidney Int. (2002) 62:1238–1248.
   Google Scholar
• YANG JW, DAI CS, LIU YH: Hepatocytegrowth factor gene therapy and angiotensin II blockade synergistically attenuate renal interstitial fibrosis in mice.' Am. Soc. Nephrol (2002) 13:2464–2477.
   PubMed Web of Science ®Google Scholar
• STEPKOWSKI SM, WANG ME, CONDON TP et al.: Protection against allograft rejection with intercellular adhesion molecule-1 antisense oligodeoxynucleotides. Transplantation (1998) 66:699–707.
   PubMed Web of Science ®Google Scholar
• VOS IH, GOVERS R, GRONE HJ et al.:NF kappaB decoy oligodeoxynucleotides reduce monocyte infiltration in renal allografts. FASEB J. (2000) 14:815–822.
   PubMed Web of Science ®Google Scholar
• AZUMA H, TOMITA N, KANEDA Y et al.: Transfection of nf kappa b-decoy oligodeoxynucleotides using efficient ultrasound-mediated gene transfer into donor kidneys prolonged survival of rat renal allografts. Gene Ther: (2003) 10:415–425.
   PubMed Web of Science ®Google Scholar
• TOMASONI S, AZZOLLINI N, CASIRAGHI F et al.: CTLA-4-Ig gene transfer prolongs survival and induces donor-specific tolerance in a rat renal allograft. Am. Soc. Nephrol (2000) 11:747–752.
   PubMed Web of Science ®Google Scholar
• SONNTAG KC, EMERY DW, YASUMOTO A et al.: Tolerance to solid organ transplants through transfer of MHC class II genes. Chu. Invest. (2001) 107:65–71.
   PubMed Web of Science ®Google Scholar
• SUN MS, PAN CJ, SHIEH JJ et al.: Sustained hepatic and renal glucose-6-phosphatase expression corrects glycogen storage disease type Ia in mice. Hum. Ma Genet. (2002) 11:2155–2164.
   PubMed Web of Science ®Google Scholar
• PARK J, MURRAY GJ, LIMAYE A et al.: Long-term correction of globotriaosylceramide storage in fabry mice by recombinant adeno-associated virus-mediated gene transfer. Proc. Nati Acad. Sci. USA (2003) 100:3450–3454.
   PubMed Web of Science ®Google Scholar
• ••Good experimental paper showinglong-term effect of AAV-based gene therapy for Fabry mice.
   Google Scholar
• IDENO J, MIZUKAMI H, HONDA K et al.: Persistent phenotypic correction of central diabetes insipidus using adeno-associated virus vector expressing arginine-vasopressin in brattleboro rats. MM. Tiler: (2003) 8:895–902.
   PubMed Web of Science ®Google Scholar
• ••Good experimental paper onAAV-based gene therapy for central diabetes insipidus, with interesting results from physiological studies.
   Google Scholar
• ST GEORGE JA: Gene therapy progress and prospects: adenoviral vectors. Gene Ther. (2003) 10:1135–1141.
   PubMed Web of Science ®Google Scholar
• ••Excellent review on adenoviral vectors.
   Google Scholar
• TENENBAUM L, LEHTONEN E, MONAHAN PE: Evaluation of risks related to the use of adeno-associated virus-based vectors. Curc Gene Ther: (2003) 3:545–565.
   PubMedGoogle Scholar
• DONSANTE A, VOGLER C, MUZYCZKA N et al.: Observed incidence of tumorigenesis in long-term rodent studies of raav vectors. Gene Ther: (2001) 8:1343–1346.
   PubMed Web of Science ®Google Scholar
• PACHORI AS, MELO LG, ZHANG LN et al.: Potential for germ line transmission after intramyocardial gene delivery by adeno-associated virus. Biochem. Biophys. Res. Commun. (2004) 313:528–533.
   PubMed Web of Science ®Google Scholar
• NIIDOME T, HUANG L: Gene therapy progress and prospects: nonviral vectors. Gene Ther. (2002) 9:1647–1652.
   PubMed Web of Science ®Google Scholar